Gilde Healthcare
Gilde Healthcare is a specialist private investment firm managing €3 billion across three strategies — Venture&Growth in healthcare, Private Equity in healthcare, and Climate Solutions — serving portfolio companies in Europe and North America from offices in Utrecht, Frankfurt, and Boston.
- Company typePrivate
- Founded1985
- HeadquartersUtrecht, Netherlands
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Gilde Healthcare does
Gilde Healthcare is a specialist private investment firm founded in 1985 and headquartered in Utrecht, the Netherlands, with additional offices in Frankfurt am Main, Germany and Boston, Massachusetts. The firm manages approximately €3 billion in assets across three dedicated fund strategies: Venture&Growth (equity investments of up to €50 million in healthtech and therapeutics companies in Europe and North America, typically as significant minority positions); Private Equity (majority ownership in profitable lower mid-market healthcare companies in Northwestern Europe with EBITDA between €2–15 million, spanning pharma & life sciences, medtech & diagnostics, healthcare providers, and healthcare IT & outsourced services); and Climate Solutions (launched in February 2026 with an initial close of €250 million targeting €325 million, focused on profitable lower mid-market companies in energy transition, biodiversity, and waste/pollution in Benelux and DACH under SFDR Article 9). The firm employs roughly 60 sector specialists with transatlantic operating, scientific, and financial backgrounds, sourced from prior roles at McKinsey, Bain, PwC, Philips, EQT, 3i, PureTech Health, and other leading institutions.
The firm generates revenue through fund management fees on committed and invested capital, supplemented by carried interest from exits of portfolio companies across all three strategies. Notable realized exits include Inari Medical (NASDAQ IPO at $5B+ valuation in 2020), Symeres (sold to Keensight Capital), RAD-x (sold to a Swiss Life Asset Managers and Vesper Infrastructure Fund I consortium), and Performation (sold to Enovation/Legrand in 2025). The Venture&Growth portfolio of 69 active companies includes Inari Medical, Withings, Big Health, Amphista Therapeutics (with major collaborations with Bristol Myers Squibb and Merck), SpyGlass Pharma (NASDAQ IPO February 2026), and Endovascular Engineering. The Private Equity portfolio of 24 companies includes a Surgical Instrument Contract Manufacturing Group (Chr. Diener, Koscher & Würtz, Rudischhauser), EUROPIN/Acti-Med needle platform, KLIFO pharma consultancy, Physio CKI physiotherapy group, and a recently merged global fNIRS neuroimaging platform (Artinis/NIRx). The firm is regulated by the Dutch Authority for the Financial Markets (AFM) under AIFMD license, is a UN PRI signatory since 2019, and operates with no external parent or public ownership.
Gilde Healthcare firmographics
Firmographics- Name
- Gilde Healthcare
- Legal name
- Gilde Healthcare Partners BV
- Website
- https://gildehealthcare.com
- Company type
- Private
- Founded year
- 1985
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Gilde Healthcare is a specialist private investment firm managing €3 billion across three strategies — Venture&Growth in healthcare, Private Equity in healthcare, and Climate Solutions — serving portfolio companies in Europe and North America from offices in Utrecht, Frankfurt, and Boston.
- Ownership category
- akta.pro rank
Gilde Healthcare industry classification
Industry- Product category
- Healthcare Private Equity and Venture Capital
- NAICS
- Portfolio Management and Investment Advice (523940)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Corporate Finance & Capital Advisory (BPAHADAB)
Keywords
Where Gilde Healthcare is headquartered
LocationHeadquarters
- HQ city
- Utrecht
- HQ country
- Netherlands
- HQ region
- Europe
Offices3 records
Markets served
Gilde Healthcare business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
Revenue model
- Fund Management: Gilde Healthcare generates revenue through management fees and carried interest from its three fund strategies: Venture&Growth, Private Equity, and Climate Solutions. The firm manages €3 billion in assets under management across these strategies.
- Investment Returns: Returns generated through capital appreciation and exits of portfolio companies, including IPOs, acquisitions, and trade sales. Examples include successful exits such as Inari Medical (NASDAQ listing, $5B+ valuation), Symeres (sold to Keensight Capital), Performation (sold to Enovation/Legrand), and RAD-x (sold to Swiss Life Asset Managers).
Go-to-market motion3 records
Distribution channels3 records
Marketing channels5 records
Gilde Healthcare product offering
Product offeringCore offering
Gilde Healthcare is a specialist private investment firm managing €3 billion across three fund strategies: Venture&Growth (healthtech and therapeutics equity investments up to €50 million in Europe and North America), Private Equity (majority buyouts of profitable lower mid-market healthcare companies in Northwestern Europe with €2-15 million EBITDA), and Climate Solutions (lower mid-market investments in energy transition, biodiversity, and waste/pollution in Benelux and DACH region). The firm provides capital, sector expertise, hands-on operating support, buy-and-build execution, and international expansion guidance to portfolio companies.
Product overview
Gilde Healthcare is a specialized private investment firm with €3 billion under management across three fund strategies: Venture&Growth in Healthcare (investing in healthtech and therapeutics), Private Equity in Healthcare (investing in lower mid-market healthcare providers and medical product suppliers), and Climate Solutions (investing in energy transition, biodiversity, and waste/pollution companies). The firm's portfolio includes various healthcare companies such as Performation (healthcare business intelligence), Inari Medical (medical devices for venous conditions), Withings (connected health devices), and Amphista Therapeutics (targeted protein degradation therapeutics).
Differentiator
Problem solved
Functional benefit
Products and services
- Venture&Growth Fund
- Private Equity Fund (Healthcare)
- Climate Solutions Fund
Quantifiable outcome
- Inari Medical grew from $250,000 Q1 2018 to projected $600 million in 2024, achieving $5B+ valuation on NASDAQ
- +3 more outcomes
Companies that use Gilde Healthcare
Customer profileNamed customers6 records
Segments4 records
Ideal customer profiles4 records
Gilde Healthcare technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Gilde Healthcare partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- Artinis Medical Systems and NIRx Medical TechnologiescoreGilde Healthcare merged Artinis Medical Systems (Netherlands) and NIRx Medical Technologies (Germany/United States) into a global leader in functional Near-Infrared Spectroscopy (fNIRS) solutions. Combined entity aims to accelerate innovation and develop into leading platform for neuroimaging research tools.
- Amphista Therapeutics - Merck CollaborationcoreAmphista Therapeutics, a Gilde Healthcare portfolio company, entered a strategic collaboration with Merck with potential value up to $1.0 billion for targeted protein degradation therapeutics using Amphista's Eclipsys platform.
- Amphista Therapeutics - Bristol Myers Squibb CollaborationcoreAmphista Therapeutics entered a strategic collaboration with Bristol Myers Squibb with potential value up to $1.25 billion for next-generation targeted protein degradation medicines.
Scale indicators9 records
Recent moves8 records
Expansion highlights6 records
Gilde Healthcare competitors and assessment
Company assessmentDirect peers
- EQT Life Sciences: EQT's healthcare-focused venture/growth arm (formerly LSP) invests across Europe and North America in therapeutics and medtech with similar check sizes; directly competes with Gilde's Venture&Growth strategy for healthcare innovation deals.
- Gimv: Belgian-listed European PE/VC firm with a dedicated Health & Care platform investing in lower mid-market healthcare companies across Benelux and DACH—the same geographic and segment focus as Gilde Healthcare Private Equity.
- Ampersand Capital Partners: US-based specialist healthcare and life sciences PE firm investing in profitable lower mid-market companies in pharma services, diagnostics, and medical devices—directly comparable to Gilde's healthcare buyout strategy.
- Linden Capital Partners: US healthcare-dedicated PE firm focused on profitable lower mid-market businesses across healthcare services, products, and distribution; closely mirrors Gilde's profitable lower mid-market healthcare PE mandate.
- Kurma Partners: Paris-based European healthcare VC firm with BioFund III investing in therapeutics and healthtech—directly comparable to Gilde's European therapeutics venture/growth strategy.
- Avista Capital Partners: US healthcare-focused PE firm investing across pharma, medtech, and healthcare services in lower mid-market and growth segments—similar sector breadth and stage focus as Gilde.
- Frazier Healthcare Partners: US healthcare-dedicated PE/VC firm with growth and buyout strategies across pharma, medtech, and healthcare services—directly comparable in approach to Gilde's combined Venture&Growth and Private Equity funds.
- Forbion: Dutch-headquartered European life sciences VC firm investing in therapeutics and medtech companies; comparable to Gilde's therapeutics venture strategy with overlapping European biotech deal flow.
- Apposite Capital: London-based specialist healthcare PE firm focused exclusively on profitable lower mid-market healthcare businesses in Europe—directly comparable to Gilde Healthcare's PE fund in mandate, geography, and target size.
Broad incumbents
- Novo Holdings: Danish holding company of the Novo Nordisk Foundation with substantial healthcare venture/PE operations across multiple stages and geographies—a much larger incumbent in healthcare investing with overlapping therapeutic and medtech exposure.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Gilde Healthcare social profiles
Digital presenceGilde Healthcare compliance and trust
Trust signalCompliance3 records
Gilde Healthcare financial estimates
Financial estimateRevenue estimate
Valuation estimate
Gilde Healthcare leadership team
Management profileNumber of profiles
Profiles19 records
Gilde Healthcare subsidiaries and ownership
Company hierarchySubsidiaries6 records
Gilde Healthcare funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Gilde Healthcare M&A and investment
M&A and investmentM&A12 records
Investments136 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Gilde Healthcare
What does Gilde Healthcare do?
Gilde Healthcare is a specialist private investment firm managing €3 billion across three fund strategies: Venture&Growth (healthtech and therapeutics equity investments up to €50 million in Europe and North America), Private Equity (majority buyouts of profitable lower mid-market healthcare companies in Northwestern Europe with €2-15 million EBITDA), and Climate Solutions (lower mid-market investments in energy transition, biodiversity, and waste/pollution in Benelux and DACH region). The firm provides capital, sector expertise, hands-on operating support, buy-and-build execution, and international expansion guidance to portfolio companies.
Is Gilde Healthcare a public or private company?
Gilde Healthcare is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Gilde Healthcare founded?
Gilde Healthcare was founded in 1985. It employs 51 to 100 people.
Where is Gilde Healthcare based?
Gilde Healthcare is headquartered in Utrecht, Netherlands, in the Europe region.
How does Gilde Healthcare make money?
Two revenue lines are on record. Fund Management is the primary driver. The others are investment Returns.
Who are Gilde Healthcare's main competitors?
Direct peers on record are EQT Life Sciences, Gimv, Ampersand Capital Partners, Linden Capital Partners, Kurma Partners, Avista Capital Partners, Frazier Healthcare Partners, Forbion and Apposite Capital. Novo Holdings is listed as a broad incumbent.
Does Gilde Healthcare have an API?
No public API is recorded for Gilde Healthcare.
What industry is Gilde Healthcare in?
Gilde Healthcare's product category is Healthcare Private Equity and Venture Capital. Its primary akta.pro industry code is BPAHADAB, Corporate Finance & Capital Advisory. Its NAICS code is 523940 and its SIC code is 6282.